| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Cardiovascular disorders and muscular diseases are considered to be related because transcription factor GATA4 is commonly expressed both in cardiomyocytes and skeletal muscle stem cells. By high- throughput screening using myoblasts, we identified a novel 18 nt-oligodeoxynucleotide, named myoDN, which intensively induces myogenic differentiation. myoDN also enhanced myocardial differentiation of pluripotent stem cells. myoDN is considered to be regulate cell fates by affecting the common target(s) existing both in cardiac and skeletal muscle. myoDN improved the deteriorated myoblast differentiation of diabetic patients. It indicates that myoDN will be a useful molecule for prevention and therapy of muscle atrophy caused by cardiovascular and metabolic disorders.
|
